268 results about "Adiponectin" patented technology

We have discovered a “human adiponectin ELISA kit”, which can specifically measure adiponectin in human blood serum (or blood plasma) or in extracted fluid from lipocytes or culture supernatant fluid. After fractioning human serum by use of gel filtration column, each fraction was measured by the present kit, and as a result, adiponectin immunity activity was detected as a plurality of peaks at above 670 kD of molecular weight. From the results, it is presumed that adiponectin is present in the blood as a polymer or forms a complex with polymer proteins.

The present inventors focused on certain nutritional compositions known to have activity of controlling blood glucose levels. These foods were administered to rats for long periods, and real-time PCR was used to analyze the expression of genes associated with lipid metabolism in the liver and adipose tissues. As a result, the present inventors found that the expression of the PPARα gene is enhanced by these foods, and that this is accompanied by suppressed expression of fatty acid synthase and enhanced expression of a group of PPARα target genes associated with fatty acid metabolism. The present inventors also confirmed the effect of these foods in enhancing the expression of PPARγ and adiponectin, and discovered that these foods have the activity of enhancing the production of PPAR and PPAR-associated factors.

The invention relates to a particle-enhanced turbidimetric immune assay kit for detecting adiponectin and a preparation method thereof, in particular to a detection method of a turbidimetric immune assay. The particle-enhanced turbidimetric immune assay kit for detecting the adiponectin comprises a kit body, an application liquid bottle and a latex suspension bottle coating an antiviral adiponectin monoclonal antibody, wherein the application liquid bottle is filled with application liquid; the application liquid comprises a surfactant, a preservative, a macromolecular accelerator, sodium chloride and a buffering agent; the latex suspension bottle coating the antiviral adiponectin monoclonal antibody is filled with a latex suspension coating the antiviral adiponectin monoclonal antibody; and the latex suspension coating the antiviral adiponectin monoclonal antibody comprises latex coating the antiviral adiponectin monoclonal antibody, the surfactant, a stabilizer and the buffering agent. The preparation method comprises the following steps of: preparing a latex antibody; preparing the latex suspension coating the antiviral adiponectin monoclonal antibody; preparing the applicationliquid; and finally preparing adiponectin series standard products.

The invention provides a kit for measuring adiponectin by a nano latex enhanced immune turbidimetry. The kit comprises reagent R1, reagent R2 and adiponectin antigen calibration material solution, wherein the reagent R1 comprises electrolyte, a stabilizer, a surface active agent, a preservative and buffer solution; the reagent R2 comprises latex particles coated by anti-human adiponectin polyclonal antibody, electrolyte, a stabilizer, a surface active agent, a preservative and buffer solution; the latex particles are copolymer formed by styrene and acrylic acid; the adiponectin antigen calibration material solution comprises adiponectin and a stabilizer; the surfaces of the latex particles in the reagent R2 have carboxyl groups, and the particle size range of the latex particles is 80-100nm. The kit is simple to operate, rapid and accurate in measurement, high in sensitivity and specificity, and low in detection cost.

Provided are methods for the detection and diagnosis of sickle cell. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of sickle cell. At least two new biomarkers for sickle cell are thus disclosed, Eotaxin and Monocyte Chemotactic Protein-1. Altogether the concentrations of eleven analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering from sickle cell. Other important biomarkers for sickle cell are described, including but not limited to IL-12p40, SHBG, MMP-9, Adiponectin, Haptoglobin, FGF basic, IgM, Growth Hormone, Factor VII. Kits containing reagents to assist in the analysis of fluid samples are also described.

Short peptide mimetics of adiponectin suitable for development as pharmaceutical agonists in the treatment of cellular proliferative disorders such as cancer and atherosclerosis are provided.

The invention relates to human adiponectin monoclonal antibody engineering in the field of medical immunology and relates to preparation of a human adiponectin ELISA kit by employing a hybridoma cell strain XA187 No.1 and a hybridoma cell strain XA187 No.19, and application of the kit to detection of human adiponectin content.

Adiponectin cDNA was cloned into AAV serotypes 1, 2, and 5-based expression vectors. Virions containing these vectors were administered to the livers of rat subjects via portal vein injection. A single injection of 6×1011 virions of the vector caused a sustained and statistically significant reduction in body weight of the treated animals compared to the control animals. This occurred in the absence of side effects. Compared to control animals, the subject rats also exhibited reduced adipose tissue mass, reduced appetite, improved insulin sensitivity, and improved glucose tolerance.

Disclosed is a method for diagnosing whether a subject suffers from a mild or severe form of liver cirrhosis based on determining the amount of GDF-15 (growth differentiation factor 15), PlGF (placental growth factor), and / or hepatocyte growth factor (HGF) in a sample from the subject and comparing the thus determined amount(s) with a reference amount (reference amounts). The method may further include determining the amount of adiponectin in a sample from the subject, and comparing the amount to a reference amount for adiponectin. Also described is a method to identifying a subject being susceptible to liver transplantation including determining the amount of GDF-15, PlGF, and / or HGF in a sample from the subject and comparing the thus determined amount(s) with a reference amount (reference amounts).

The invention provides a human adiponectin enzyme-linked immunosorbent detection kit, a preparation method and application thereof. The kit comprises antihuman APN monoclonal antibody-coated ELISA plates, recombinant gAPN protein standard, antihuman APN monoclonal detection antibodies, HRP-streptomycin, 10 mM of phosphate buffer with a pH of 7.4, TMB enzyme-substrate chromogenic solution, 0.1 M of phosphate buffer with a pH of 7.4 and 2 M of H2SO4. The invention also comprises the preparation method of the kit and the application of the kit in the detection of human-blood APN content. The kit has the advantages that the kit is convenient and fast to use and operate, capable of getting detection results within 2 hours, high in specificity, low in cost and convenient for clinical large-scale use.

This invention provides methods of using of the sizes and levels of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles, the -641 allele of the promoter of the gene encoding apolipoprotein C-3 (APOC-3), the 405 allele of the gene encoding cholesteryl ester transfer protein (CETP), and plasma levels of insulin-like growth factor-1 (IGF-1), adiponectin, CETP and APOC-3, for determining and increasing an individual's likelihood of longevity and of retaining cognitive function during aging, and for determining and decreasing an individual's likelihood of developing a cardiovascular-, metabolic- or age-related disease.

The present disclosure relates to nutritional compositions including a protein equivalent source that includes a peptide component comprising selected peptides. The protein equivalent source may further include intact protein, hydrolyzed protein, including partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of promoting healthy body weight in a target subject by stimulating adiponectin levels by providing the nutritional compositions disclosed herein to a target subject, which includes a pediatric subject.

Short peptide mimetics of adiponectin suitable for development as pharmaceutical agonists in the treatment of cellular proliferative disorders such as cancer and atherosclerosis are provided.

The invention relates to a conjugate comprising an adiponectin polypeptide, and a first non-polypeptide moiety covalently attached to the adiponectin polypeptide, wherein the adiponectin polypeptide comprises an amino acid residue having an attachment group for said first non-polypeptide moiety, wherein said amino acid residue has been introduced in a position that in the parent adiponectin is occupied by a surface exposed amino acid residue.

Disclosed is a personalized diagnostic and treatment solution for cardiovascular disease. The invention comprises an extended CVD risk assessment panel, combining tests for traditional and new important risk markers, and methods for devising a personalized treatment plan for a patient via the use of a CVD diagnosis and treatment protocol algorithm. The new important risk markers include HDL subpopulation profile by two-dimensional gel-electrophoresis, plasma sterols, direct measurement of sdLDL-C, determination of CRP molecular forms, glycated albumin as a percentile of total albumin, and other specialized testing pertaining to apolipoprotein E and Factor V Leiden genotyping, NT-proBNP and adiponectin. This solution provides a more complete risk assessment of an individual than merely measuring traditional CVD risk markers, and enables the healthcare practitioner to optimize therapy for patients with or without established CVD. This solution presents the advantages of greater accuracy, savings in time and cost over existing testing and treatment methods.

The invention provides a method that uses enzyme-treatment of whole soybeans or partially defatted soybeans to select soybeans with improved bioactivity or bioactivities. The invention further provides a soybean plant and seed with a non-transgenic mutation conferring enhanced bioactivity as an hydrolysate when compared to hydrolysate from other seeds, for instance in a cell-based assay, including reduced cancer cell viability; increased LDL receptor activity; reduced lipid accumulation; increased adiponectin expression; decreased FAS and LPL expression; reduced production of NO and PGE2, and expression of iNOS and COX-2; higher antioxidant activity; promotion of growth of bifidobacteria; and inhibiting the growth of pathogenic bacteria; for instance when compared to other seeds tested as hydrolysates. The invention also provides soybean plants for use in producing seeds that have an overall improved bioactivity compared to other seeds as hydrolysates by combining effects on several bioactivity assays in a health index. The invention also provides products derived from, and parts of, these plants and uses thereof. Methods for producing such plants are also provided, as well as methods for standardizing or assuring quality control of soybean products with enhanced bioactivity for humans and animals.

Methods for selectively assaying a target adiponectin multimer in a biological sample. Such methods accurately evaluate the relationship between a disease and adiponectin through selective assay of adiponectin multimers and provide information that cannot be obtained through measurement of the total amount of adiponectin alone. A method for selectively assaying of a target adiponectin multimer in a biological sample comprising distinguishing target adiponectin multimer from the other adiponectin multimers by using a protease and / or an antibody.

A latex reagent for analyzing adiponectin, comprising a suspension of latex particles carrying a substance which specifically binds to adiponectin, is disclosed. Further, a method for analyzing adiponectin, comprising (1) obtaining a biological liquid possibly containing adiponectin, and (2) bringing the biological liquid, while maintaining the state in which the biological liquid is obtained, into contact with a suspension of latex particles carrying a substance which specifically binds to adiponectin, and optically analyzing a degree of latex-particles-agglutination, is disclosed. According to the latex reagent and the method for analyzing adiponectin, a predilution or pretreatment of the biological liquid to be analyzed is not necessary. Further, the analysis can be performed rapidly and conveniently, and facilities therefor are not limited.

Administering an effective amount of APN into an intervertebral disc is disclosed.

The invention provides a latex-enhanced turbidimetric immunoassay kit for quantitatively detecting adiponectin ADPN. The latex-enhanced turbidimetric immunoassay kit comprises an adiponectin R1 reagent and an adiponectin R2 reagent, wherein the adiponectin R1 reagent comprises a buffer solution A, a protective agent A, a reaction enhancer and a preservative; the adiponectin R2 reagent comprises abuffer solution B, a protective agent B, a preservative and sensitized polystyrene latex particles coated with an anti-human adiponectin antibody; the anti-human adiponectin antibody in the sensitizedpolystyrene latex particle coated with the anti-human adiponectin antibody is connected with the sensitized polystyrene latex particle through a streptavidin-biotin system. The invention also provides a preparation method and an application method of the latex-enhanced turbidimetric immunoassay kit for quantitatively detecting adiponectin ADPN. The kit has the advantages that the kit is convenient, rapid, high in sensitivity and specificity and capable of quantitatively and accurately detecting ADPN; and the kit is strong in instrument compatibility and low in detection cost, and makes up theclinical requirements on ADPN turbidimetric products.

This invention provides a method for diagnosing geriatric diseases associated with insulin resistance, such as type II diabetes, at an early stage and a method for monitoring the therapeutic effects of agents for type II diabetes by quantitatively assaying GBP28 with the use of a monoclonal antibody that can assay adiponectin (GBP28) in a sample.

This invention provides methods of using of the sizes and levels of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles, the−641 allele of the promoter of the gene encoding apolipoprotein C-3 (APOC-3), the 405 allele of the gene encoding cholesteryl ester transfer protein (CETP), and plasma levels of insulin-like growth factor-1 (IGF-1), adiponectin, CETP and APOC-3, for determining and increasing an individual's likelihood of longevity and of retaining cognitive function during aging, and for determining and decreasing an individual's likelihood of developing a cardiovascular-, metabolic- or age-related disease.

A composition for preventing or treating an eye disease includes adiponectin as an active ingredient. Adiponectin as an active ingredient is eventually revealed to show prevention or therapeutic efficacies for eye diseases such as dry eye (syndrome), inflammatory eye disease and side effects due to the use of contact lenses by promoting tear secretion, alleviating ocular surface irregularities, decreasing inflammatory cytokines on the ocular surface and lacrimal gland, and increasing conjunctival goblet cell density. In addition, the composition having eye contact lubrication effects may be used as cleaners or lubricants for preventing non-bacterial inflammation due to wearing contact lenses.

To prevent or alleviate various pathologies caused by lifestyle-related diseases, etc., the present invention provides a substance having an effect of promoting the expression and elevating the expression level of adiponectin, and applications thereof. An adiponectin expression promoting agent containing, as an active ingredient, at least one cyanidin compound selected from the group consisting of cyanidin and cyanidin glycosides can be applied to pharmaceutical or food compositions for use in applications in which the pharmacological effects of adiponectin are utilized.

The invention provides infant formula milk powder rich in milk fat globule membrane protein and phospholipid. By adding alpha-lactalbumin, milk fat globule membrane and a physiological activator, suchas bifidobacterium animalis Bb-12, milk fat globule membrane lipids and protein, N-acetylneuraminic acid (sialic acid), SN-2 structure lipid, human milk oligosaccharides (HMOs) and human milk oligose(HMO). By simultaneously adjusting the using amount ratio of all the components, especially sphingomyelin, gangliosides, the milk fat globule membrane protein, the human milk oligosaccharides, the human milk oligose, adiponectin and lysozyme, and the proportion between mucin, xanthine oxidoreductase, mucin 15, CD 36, butyrophilin, adipose differentiation-related protein and fatty acid binding proteins, the content of the active ingredients in the milk powder is closer to the content of active ingredients in human milk, the constitution of the infant formula milk powder is optimized, and the formula milk powder obtained by using the method is closer to the human milk.

Disclosed is an adiponectin-Glucagon-like peptide-1-like peptide recombinant protein expression vector and construction, wherein adiponectin and GLP-1-A encoded gene are obtained by utilizing PCR technology, the method comprises obtaining adiponectin through amplification of adiponectin spherical domain gene, then obtaining GLP-1-A encoded gene by mutating codons encoding No. 8 amino acid alanine in GLP-1-(7-37) encoded gene, then cloning GLP-1-A and adiponectin encoded genes directionally to expression vector by utilizing enzyme digestion technology, obtaining adiponectin-glucagon-like peptide-1 analogue peptide fusion protein expression vector, finally expressing adiponectin-GLP-1-A fusion protein through transforming protein expression bacteria.

The invention provides a breeding method for screening thin type ducks by detecting genes of mutant ducks, which is characterized by including the following steps: the design of PRC primers, primer design according to the Adiponectin genome of the duck; the extraction of the genomic DNA of the duck; the PRC amplification of a primer A of the genomic DNA of the duck; the PCR-SSCP analysis of the Adiponectin genotypes of the amplification products; the selection of needed breeding ducks according to the following characteristics of each genotype. Genetic marker assisted breeding selection can be carried out to the breeding ducks by utilizing the method, thus radically solving the problems in traditional genetic breeding, which are caused by the over-pursuit on the rate of growth of meat ducks, for example, meat ducks become higher in fat and worse in quality, excessive fat is deposited, the rate of conversion of feeding stuff is affected and the ratio of eggs to feeding stuff in the production of female ducks is comparatively low and the like.

The invention pertains to methods for measuring different forms of human adiponectin that are present in human plasma / serum, and more specifically methods are based on an ELISA assay that utilizes different monoclonal antibodies directed against adiponectin, in combination with different polyclonal antibodies directed against different domains of human adiponectin. The invention also provides unique isoforms of adiponectin and antibodies thereto, including polyclonal and monoclonal antibodies.

The invention belongs to the technical field of drugs, and particularly relates to aminopeptidase N inhibitor, a preparation method and application to tumor resistance. The technical scheme includes that the aminopeptidase N inhibitor is chemically named as (S)-4-methyl-2-(3-naphthyl-1-ylmethyl-ureido)-valeryl group hydroxylamine. The constitutional formula (I) of the aminopeptidase N inhibitor is shown here. The pharmacodynamic effect of the aminopeptidase N inhibitor is evaluated by in-vitro APN (adiponectin) inhibitory experiments, in-vitro resistance to tumor cell invasion, antiangiogenesis and mouse in-vivo resistance to melanoma manual transfer and antiangiogenesis experiments.

To provide a fat accumulation inhibitor and a food or drink for inhibiting fat accumulation, a visceral fat accumulation inhibitor and a food or drink for inhibiting visceral fat accumulation, or an agent for accelerating increase and / or inhibiting decrease of an adiponectin concentration in blood and a food or drink for accelerating increase and / or inhibiting decrease of an adiponectin concentration in blood.A fat accumulation inhibitor for a fat cell, which comprises a milk-derived phospholipid as an active ingredient, and a food or drink for inhibiting fat accumulation in a fat cell, which comprises a milk-derived phospholipid. A visceral fat accumulation inhibitor comprising a sphingosine-containing phospholipid or a derivative thereof as an active ingredient, and a food or drink for inhibiting visceral fat accumulation. An agent for accelerating increase and / or inhibiting decrease of an adiponectin concentration in blood, which comprises a sphingosine-containing phospholipid or a derivative thereof as an active ingredient, and a food or drink for accelerating increase and / or inhibiting decrease of an adiponectin concentration in blood.